PT-141 vs. Sildenafil vs. Tadalafil: What's the Difference?

PT-141, sildenafil and tadalafil often appear in the same conversation about sexual wellness.

But they are not three versions of the same medication.

Sildenafil—best known by the brand name Viagra®—and tadalafil—best known as Cialis®—are PDE5 inhibitors used to treat erectile dysfunction.

PT-141 is a name used in clinical research for bremelanotide, a melanocortin-receptor agonist. The FDA-approved bremelanotide product, Vyleesi®, is an injectable medication indicated for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD. It is not FDA-approved for men or for erectile dysfunction.

That distinction gets to the heart of the comparison:

Erectile function, sexual desire and arousal are connected—but they are not the same thing.

The Short Answer

Sildenafil and tadalafil primarily support the physical erectile response. They inhibit PDE5, which enhances a nitric oxide/cGMP pathway involved in penile blood flow during sexual stimulation. Neither works in the absence of sexual stimulation.

Bremelanotide works differently. It activates melanocortin receptors, including receptors found in the central nervous system. However, the FDA label specifically states that the mechanism by which Vyleesi improves HSDD is unknown.

So asking whether PT-141 is “better than Viagra” or whether Cialis is “stronger than PT-141” can be misleading.

They involve different biological pathways and different FDA-approved uses.

The more useful question is:

What part of sexual response is actually causing concern?

PT-141 vs. Sildenafil vs. Tadalafil at a Glance

Sildenafil
Common brand association: Viagra®
Drug class: PDE5 inhibitor
Main FDA-approved sexual-health use: Erectile dysfunction
Primary pathway discussed: Nitric oxide / cGMP / blood flow
Requires sexual stimulation for erectile effect: Yes
Typical distinguishing feature: Shorter dosing window

Tadalafil
Common brand association: Cialis®
Drug class: PDE5 inhibitor
Main FDA-approved sexual-health use: Erectile dysfunction
Primary pathway discussed: Nitric oxide / cGMP / blood flow
Requires sexual stimulation for erectile effect: Yes
Typical distinguishing feature: Longer dosing window

Bremelanotide / PT-141
Common brand association: Vyleesi®*
Drug class: Melanocortin receptor agonist
Main FDA-approved sexual-health use: Acquired, generalized HSDD in certain premenopausal women*
Primary pathway discussed: Melanocortin receptors / central nervous system
Requires sexual stimulation for erectile effect: Not an ED indication
Typical distinguishing feature: Different mechanism and approved indication

Vyleesi is the FDA-approved subcutaneous bremelanotide injection. Other PT-141 formulations, including compounded formulations, are not the FDA-approved Vyleesi product.

What Does Sildenafil Do?

Sildenafil is a phosphodiesterase type 5, or PDE5, inhibitor.

During sexual stimulation, nitric oxide is released in erectile tissue. This contributes to increased levels of cyclic GMP, or cGMP, which helps smooth muscle relax and allows increased blood flow into the penis.

PDE5 breaks down cGMP.

Sildenafil inhibits PDE5, allowing that signaling pathway to have a greater effect. The FDA label makes an important point: sildenafil does not independently produce this process and has no effect on erections in the absence of sexual stimulation.

For Viagra, the FDA-approved indication is erectile dysfunction. The prescribing information states that it is generally taken approximately one hour before sexual activity, although it may be taken from about 30 minutes to four hours beforehand.

Does Sildenafil Increase Sex Drive?

Not in the same sense as treating low sexual desire.

Sildenafil is not FDA-approved as a treatment for low libido. Its established role in sexual medicine is erectile dysfunction.

That matters because a person can have:

• strong sexual desire but difficulty developing or maintaining an erection
• normal erectile capability but little interest in sex
• changes in both areas at the same time

So the statement:

“Viagra helps my erections, but I still don’t feel interested in sex.”

is not necessarily contradictory.

Erectile response and sexual desire are different components of sexual function.

How Is Tadalafil Different From Sildenafil?

Tadalafil is also a PDE5 inhibitor and works through the same general nitric oxide/cGMP pathway involved in erectile response.

Like sildenafil, it requires sexual stimulation for an erectile effect.

The most important practical distinction is its longer treatment window.

For as-needed erectile-dysfunction treatment, Cialis has demonstrated improved erectile function compared with placebo for up to 36 hours after dosing. It also has an FDA-approved once-daily dosing option for ED.

That does not mean an erection lasts for 36 hours.

It means tadalafil can remain available to support erectile response during that period when sexual stimulation occurs.

Sildenafil vs. Tadalafil: Which Lasts Longer?

Tadalafil has the longer labeled window of activity.

Sildenafil is generally taken about one hour before sexual activity and may be taken between approximately 30 minutes and four hours beforehand.

For as-needed tadalafil, erectile-function improvement has been demonstrated for up to 36 hours after dosing.

That longer window is one reason some people associate tadalafil with greater spontaneity.

But longer does not automatically mean better.

Individual response, health history, other medications, side effects and personal preferences can all influence which medication a healthcare professional considers appropriate.

What Is PT-141?

PT-141 is the name used in earlier clinical research for the compound now known as bremelanotide.

Unlike sildenafil and tadalafil, bremelanotide is not a PDE5 inhibitor.

FDA prescribing information describes bremelanotide as a melanocortin-receptor agonist that activates several melanocortin receptor subtypes. At therapeutic dose levels, MC1R and MC4R binding are considered particularly relevant, and neurons expressing MC4R are present in many areas of the central nervous system.

Importantly, the label also states:

The mechanism by which Vyleesi improves HSDD in women is unknown.

That is an important distinction from the much more clearly characterized PDE5 pathway of sildenafil and tadalafil.

What Is Bremelanotide FDA-Approved For?

The FDA-approved bremelanotide product is Vyleesi, administered as a subcutaneous injection.

Its indication is acquired, generalized HSDD in premenopausal women whose low sexual desire causes marked distress or interpersonal difficulty and is not due to a coexisting medical or psychiatric condition, relationship problems, or the effects of another medication or drug substance.

The FDA label specifically states that Vyleesi is:

• not indicated for postmenopausal women
• not indicated for men
• not indicated to enhance sexual performance

So claims such as:

“PT-141 is FDA-approved for male libido.”

or

“PT-141 is an FDA-approved erectile-dysfunction treatment.”

would be inaccurate.

Has PT-141 Been Studied in Men?

Yes.

But being studied is not the same as being FDA-approved for an indication.

A randomized, double-blind, placebo-controlled study published in the International Journal of Impotence Research in 2004 evaluated intranasal PT-141 in healthy men and men with mild-to-moderate erectile dysfunction. The researchers examined safety, pharmacokinetics and erectile-response measures and concluded that PT-141 warranted further investigation for male ED.

Another small study published in Urology in 2005 evaluated low-dose intranasal PT-141 together with sildenafil in men with erectile dysfunction.

These studies helped establish scientific interest in melanocortin pathways in male sexual response.

But they were early studies conducted roughly two decades ago, and they used investigational intranasal formulations.

They did not establish an FDA-approved male indication for bremelanotide and should not be treated as proof that every modern PT-141 formulation has the same effects.

PT-141 vs. Viagra: What Is the Biggest Difference?

The most useful distinction is the pathway involved.

Sildenafil inhibits PDE5 and supports the nitric oxide/cGMP pathway involved in penile blood flow during sexual stimulation.

Bremelanotide is a melanocortin-receptor agonist whose FDA-approved use involves HSDD in a specific population of premenopausal women.

So PT-141 should not simply be thought of as a “stronger Viagra.”

They are pharmacologically different.

PT-141 vs. Cialis: What Is the Difference?

The distinction is similar.

Tadalafil is a PDE5 inhibitor used for erectile dysfunction, with a longer labeled window of activity than sildenafil.

Bremelanotide acts on melanocortin receptors and has a different FDA-approved indication.

That means a person asking:

“Should I use PT-141 or Cialis?”

may actually be asking a more fundamental question:

Is the concern primarily sexual desire, arousal, erectile response—or more than one of these?

Desire, Arousal, Erections and Orgasm Are Different

This distinction is central to understanding sexual-wellness treatments.

Desire broadly refers to interest or motivation for sexual activity.

Arousal includes psychological and physical responses associated with becoming sexually excited.

Erectile function refers to developing and maintaining an erection.

Orgasm is another distinct component of sexual response.

These systems interact, but they do not always move together.

Someone can want sex and still experience erectile difficulty.

Someone else can have normal erectile function but little interest in sex.

Another person may experience desire and arousal but have difficulty reaching orgasm.

That's why asking for “something stronger” may not identify the actual issue.

The more useful starting point is often:

What part of my sexual response feels different?

Can Sildenafil and Tadalafil Be Taken Together?

They should not be combined without medical direction.

Viagra prescribing information states that the safety and efficacy of combining it with other PDE5 inhibitors or other erectile-dysfunction therapies have not been established and that such combinations may further lower blood pressure. The label therefore does not recommend these combinations.

Cialis labeling similarly states that the safety and efficacy of combining tadalafil with other PDE5 inhibitors or ED therapies have not been studied and instructs patients not to take Cialis with other PDE5 inhibitors.

Can PT-141 Be Combined With Sildenafil or Tadalafil?

Combination approaches have been investigated in research.

A small 2005 study evaluated low-dose intranasal PT-141 together with sildenafil in men with erectile dysfunction and reported a greater erectile response with the combination than with either study treatment alone.

But that finding requires substantial context.

The study involved:

• a small number of participants
• an investigational intranasal PT-141 formulation
• specific study doses
• controlled research conditions

It does not establish that current compounded combination products have identical absorption, dosing, safety or clinical outcomes.

And it does not mean patients should independently combine prescription medications.

What About Compounded PT-141 Films, Troches or Combination Products?

This is an especially important distinction.

The FDA-approved bremelanotide product is Vyleesi, a subcutaneous injection.

If PT-141 is prescribed in another form—such as a compounded sublingual preparation—or combined with other active ingredients, that particular compounded formulation is not the FDA-approved Vyleesi product.

The FDA states that compounded medications are not FDA-approved and therefore are not reviewed by the agency before marketing for safety, effectiveness or quality.

Compounding can nevertheless have a legitimate role when a prescriber determines that an available FDA-approved drug does not meet an individual patient's medical needs.

This is why evidence concerning Vyleesi—or an older investigational intranasal PT-141 formulation—should not automatically be interpreted as evidence for every compounded product containing bremelanotide.

Are PT-141, Sildenafil and Tadalafil Safe for Everyone?

No prescription medication is appropriate for everyone.

Sildenafil and tadalafil

Both sildenafil and tadalafil are contraindicated with nitrates because the combination can cause a potentially dangerous reduction in blood pressure. Their labels also contain precautions involving cardiovascular health, alpha-blockers and antihypertensive medications, prolonged erections, and rare vision or hearing events.

FDA-approved bremelanotide

Vyleesi has a different safety profile.

It is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. FDA prescribing information states that it can temporarily increase blood pressure and decrease heart rate after each dose, with those effects usually resolving within 12 hours.

Nausea was the most commonly reported adverse reaction in the phase 3 placebo-controlled trials, occurring in 40% of Vyleesi-treated patients compared with about 1% of placebo-treated patients.

Those differences are another reason these medications should not be viewed as interchangeable.

Which Is Best: PT-141, Sildenafil or Tadalafil?

There is no meaningful universal ranking.

Sildenafil and tadalafil are established PDE5 inhibitors used for erectile dysfunction.

FDA-approved bremelanotide addresses a different sexual-health condition in a specific population.

And sexual concerns themselves can involve different combinations of vascular, neurological, hormonal, psychological, medication-related and relationship factors.

So instead of asking:

“Which medication is strongest?”

a more useful question is:

“What part of sexual response is actually not working the way I want it to?”

That provides a much better starting point for a conversation with a healthcare professional.

Frequently Asked Questions

Is PT-141 the same as Viagra?

No. Sildenafil, the active ingredient in Viagra, is a PDE5 inhibitor used for erectile dysfunction. Bremelanotide/PT-141 is a melanocortin-receptor agonist and has a different FDA-approved use.

Is PT-141 the same as Cialis?

No. Cialis contains tadalafil, a PDE5 inhibitor. Bremelanotide is a melanocortin-receptor agonist. They act through different biological pathways and have different FDA-approved indications.

Does Viagra increase libido?

Sildenafil is not FDA-approved to treat low sexual desire. Its approved sexual-health indication is erectile dysfunction, and its mechanism supports erectile response during sexual stimulation.

Does Cialis increase sex drive?

Tadalafil is not FDA-approved as a treatment for low libido. It is a PDE5 inhibitor used for erectile dysfunction and requires sexual stimulation for an erectile effect.

Is PT-141 FDA-approved for men?

No. The FDA-approved bremelanotide product, Vyleesi, is not indicated for men. PT-141 has been investigated in male research studies, but that is different from having an FDA-approved male indication.

How long does tadalafil last compared with sildenafil?

Tadalafil has the longer labeled treatment window. Cialis has demonstrated improved erectile function compared with placebo for up to 36 hours after dosing. Viagra is generally taken about one hour before sexual activity and may be taken from approximately 30 minutes to four hours beforehand.

Can sildenafil and tadalafil be taken together?

FDA labeling advises against combining PDE5 inhibitors because the safety and efficacy of such combinations have not been established and the combination may increase blood-pressure-lowering effects.

Can PT-141 be used with Viagra or Cialis?

Combination approaches involving PT-141 and sildenafil have been investigated in research, but that does not mean a particular combination is appropriate for an individual patient. Medical history, other medications, formulation and potential risks all need to be considered by a healthcare professional.

Is compounded PT-141 the same as Vyleesi?

No. Vyleesi is a specific FDA-approved subcutaneous bremelanotide product. Compounded formulations containing bremelanotide are not FDA-approved and should not be assumed to have the same formulation, absorption, safety or effectiveness as Vyleesi.

Different Symptoms May Need Different Conversations

Sexual wellness is not controlled by one biological pathway.

A change in desire is different from difficulty becoming physically aroused. Erectile difficulty is different again. Sometimes more than one part of sexual response changes at the same time.

AmalfiDuo Sexual Wellness Programs

If you’re exploring ways to support your sexual wellness, AmalfiDuo offers private, provider-guided care programs for adults.

Explore available programs and complete a private online health evaluation if you find an option that may be right for you. A licensed clinician will review your health information to determine whether treatment is appropriate.

Explore Sexual Wellness Programs

A prescription is never guaranteed.

‍

References

1. Vyleesi® (bremelanotide injection) — U.S. Prescribing Information. DailyMed, U.S. National Library of Medicine.
2. Viagra® (sildenafil citrate) — U.S. Prescribing Information. DailyMed, U.S. National Library of Medicine.
3. Cialis® (tadalafil) — U.S. Prescribing Information. DailyMed, U.S. National Library of Medicine.
4. Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005;65(4):755–759.
5. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research. 2004;16(1):51–59.
6. Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration.

‍

This article is provided for general educational purposes only and is not a substitute for individualized medical advice, diagnosis or treatment. Always discuss prescription medications and changes in sexual health with a qualified healthcare professional. AmalfiDuo Journal articles are written by AmalfiDuo Editorial and are not medically reviewed — see our Editorial Policy.

Viagra®, Cialis® and Vyleesi® are trademarks of their respective owners. AmalfiDuo is not affiliated with or endorsed by the owners or manufacturers of these brands.